Substudy of the the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP; CACZ885M2301)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Cardiovascular disorders; Myocardial infarction
- Focus Therapeutic Use
- 14 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
- 14 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 24 May 2016 New trial record